<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

RPMI 8226

Description

RPMI 8226 (Multiple Myeloma CDX Model) 

The RPMI 8226 line was derived from the peripheral blood of a patient with multiple myeloma. It represents malignant plasma cells and secretes immunoglobulin. RPMI 8226 is widely used in preclinical drug development for myeloma. Its reproducibility makes it valuable for translational hematology research. 

Key Features: 

  • Derived from multiple myeloma blood sample. 
  • Produces immunoglobulin light chains. 
  • Plasma cell phenotype. 
  • Tumorigenic in xenografts. 

Applications: 
RPMI 8226 supports evaluation of novel myeloma therapies and biomarkers. Researchers use it in resistance mechanism and immunotherapy studies. It is also applied in drug screening programs for hematology. Its reproducibility ensures reliability in translational research.

Details
Tumor Type
Lymphoid
Tumor Subtype
Multiple Myeloma
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
EGFR
Mutation: p.T751I
Effect: Missense Variant
Impact: Drug Response
KRAS
Mutation: p.G12A
Effect: Missense Variant
Impact: Pathogenic & Not Provided & Likely Pathogenic
TP53
Mutation: p.E285K
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic & Drug Response & Pathogenic / Likely Pathogenic
Expression Data
Growth Curve
View on Lumin